Laser reduces IOP

Article

A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd.

A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd.

Once the laser reaches optimal residual intact layer thickness - when it comes into contact with the intraocular percolated liquid - it has attained the desired scleral thickness and stops ablating. IOPtima tested the CO2 laser-filtration non-penetrating device on surgery-indicated human study subjects (n=30) with a mean preoperative IOP of 26.0 mmHg who used an average of 2.28 medications. During the outpatient procedure of this multinational trial, the study team used local anaesthetic and performed six months of follow-up.

Trial results showed the procedure was safe and efficacious, with mean IOP being reduced to 14.0 mmHg at six months and reports of only minor adverse events. "Complete success" in the trial - defined as achieving IOP of <18 mmHg and total medication independence - was achieved by 86.7% of study participants, and 93.5% of subjects achieved IOP of below 18 mmHg. Average medications required dropped to 0.27 at six months.

Dr Joshua Degani, CEO of IOPtima, believes the easy-to-use new technology offers a significant breakthrough in glaucoma treatment. Patients will continue to be followed up for at least six more months to establish more definitive safety and efficacy data, which IOPtima hopes to use to achieve European and US regulatory approval.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.